Fat loss
Retatrutide
- 5mg*10vials USD 45.00
- 10mg*10vials USD 85.00
Reference price. The concierge confirms the amount before payment.
4.2 / 5 · 3675 reviewsAfter the order is submitted, quote the order number when you write to the concierge.
Features
Triple receptor agonist, offering the most potent fat-loss effect (24% weight reduction in clinical settings)
Overview
Retatrutide is an investigational triple-receptor agonist peptide (targeting GLP-1, GIP, and glucagon receptors) currently under development for the treatment of obesity and type 2 diabetes. Phase II clinical trials have demonstrated significant weight loss, with patients in the high-dose group achieving a weight reduction of up to 24% over 48 weeks. This educational program outlines a once-weekly subcutaneous administration regimen, incorporating a gradual dose-escalation approach to minimize gastrointestinal side effects.
Precautions
Reconstitution: Add 1.0 mL of bacteriostatic water → ~ 5.0 mg/mL concentration
Typical weekly dosage range: 2–8 mg once weekly (gradually increased over 8–12 weeks)
Easy measurement: At 5.0 mg/mL, 1 unit = 0.01 mL ≈ 50 mcg (using a U-100 insulin syringe)
How to use
1. Draw 1.0 mL of bacteriostatic water using a sterile syringe.
2. Inject slowly along the inner wall of the vial; avoid creating foam.
3. Gently swirl or roll the vial until the contents are dissolved (do not shake).
4. Label with the date and store refrigerated at 2–8°C, protected from light.
5. Use within 4 weeks of reconstitution.
Storage
Lyophilized: Store at -20°C or lower; stable for up to 24 months.
After reconstitution: Store at 2–8°C; use within 4 weeks.
Allow the vial to reach room temperature before opening to minimize condensation.
Reviews
4.2 / 5
3675 reviews
Showing the latest 100 reviews.
-
★★★★★
VX8•••••••F564
United States
2026-10-23 13:08
Support confirmed the destination before dispatch. The contents were undamaged. The whole order was tidy.
-
★★★★★
VX1•••••••B17A
Singapore
2026-10-23 09:15
The delivery window was kept. The contents were undamaged. Glad the listing was precise.
-
★★★★★
VX7•••••••7A7E
Other
2026-10-23 05:22
The parcel was packed securely. The batch note was readable. I would use this listing again.
-
★★★★★
VXF•••••••9130
Other
2026-10-23 01:30
Communication was brief. The storage note was clear. The rest was straightforward.
-
★★★★★
VXB•••••••FB19
France
2026-10-22 21:37
The outer box was slightly scuffed. The seal was intact. Packing did its job.
-
★★★★★
VXD•••••••D164
Singapore
2026-10-22 17:44
The reply was short, then the shipment moved. The description matched. I would still order again.
-
★★★★★
VX6•••••••ECF3
Netherlands
2026-10-22 13:52
The tracking page paused for a day. The description matched. The rest was straightforward.
-
★★★★★
VX3•••••••C8C2
United Kingdom
2026-10-22 09:59
Notice of dispatch came a day later than I hoped. The label matched the listing. The rest was straightforward.
-
★★★★★
VXE•••••••16AF
United Kingdom
2026-10-22 06:06
Notice of dispatch came a day later than I hoped. The vial was undamaged. Only the timing was average.
-
★★★★★
VX8•••••••7ABD
United Kingdom
2026-10-22 02:13
Tracking matched the arrival. The inner seal was intact. Glad the listing was precise.
Buyer review
Enter the order number and the phone number from checkout. Both must match an order that includes this product.
Also listed
Fat loss
Cagrilintide
Cagrilintide is a long-acting, acylated amylin analogue—a pancreatic hormone—designed for once-weekly subcutaneous injection. It activates central amylin receptors, promoting satiety, slowing gastric emptying, and reducing food intake. In Phase 2 and Phase 3 clinical trials, cagrilintide induced dose-dependent weight loss, with side effects primarily being gastrointestinal in nature.
Reference priceUSD 113.00
Fat loss
CJC-1295+IPA(CP10)
This formulation combines CJC-1295 (without DAC)—a modified growth hormone-releasing hormone (GHRH) analog—with Ipamorelin, a selective growth hormone secretagogue (GHS). CJC-1295 (without DAC) produces a sustained, dose-dependent increase in GH and IGF-1 levels, while Ipamorelin selectively stimulates GH release without increasing ACTH or cortisol.
Reference priceUSD 116.00
Fat loss
Tirzepatide
Tirzepatide is a dual incretin receptor agonist composed of 39 amino acids. It activates both GLP-1 and GIP receptors, thereby enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite. With a half-life of approximately 5 days, it is convenient to administer via a once-weekly subcutaneous injection. Clinical trials have demonstrated that tirzepatide offers superior efficacy in terms of glycemic control and weight loss compared to selective GLP-1 receptor agonists.
Reference priceUSD 40.00
Fat loss
Tesamorelin
Tesamorelin is a synthetic 44-amino acid peptide analog that resembles growth hormone-releasing hormone (GHRH). It stimulates the release of endogenous growth hormone and increases IGF-1 levels, thereby promoting lipolysis and providing metabolic benefits. Tesamorelin has been approved by the FDA for the reduction of visceral adipose tissue in individuals with HIV-associated lipodystrophy.
Reference priceUSD 41.00